ニコチン依存症(Nicotine Addiction)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nicotine Addiction Overview 7
Therapeutics Development 8
Pipeline Products for Nicotine Addiction – Overview 8
Pipeline Products for Nicotine Addiction – Comparative Analysis 9
Nicotine Addiction – Therapeutics under Development by Companies 10
Nicotine Addiction – Therapeutics under Investigation by Universities/Institutes 11
Nicotine Addiction – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nicotine Addiction – Products under Development by Companies 14
Nicotine Addiction – Products under Investigation by Universities/Institutes 15
Nicotine Addiction – Companies Involved in Therapeutics Development 16
AbbVie Inc. 16
Astraea Therapeutics, LLC 17
Embera NeuroTherapeutics, Inc. 18
FORUM Pharmaceuticals Inc. 19
Heptares Therapeutics Ltd. 20
Omeros Corporation 21
Nicotine Addiction – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 31
(oxazepam + metyrapone) – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AT-1001 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs to Inhibit FAAH for CNS Disorders – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
encenicline hydrochloride – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OMS-405 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
OMS-527 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SLV-330 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Vaccine for Nicotine Addiction – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Vaccine for Nicotine Addiction – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Nicotine Addiction – Recent Pipeline Updates 46
Nicotine Addiction – Dormant Projects 50
Nicotine Addiction – Discontinued Products 51
Nicotine Addiction – Product Development Milestones 52
Featured News & Press Releases 52
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 52
May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55